Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
/in Dendritic Cells, Glioblastoma, International Publications, Malignant Melanoma /von 2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-624Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-04-12 / Biomed Pharmacother 2023 Jun;162:114685The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-04-03 / Pharmaceutics 2023 Apr;15(4)Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
/in Dendritic Cells, International Publications /von 2023-04-01 / J Cancer Res Ther 2023 Apr;19(Supplement):S52-S58A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2023-03-07 / Cancer Immunol Immunother 2023 Mar;Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-03-02 / NPJ Vaccines 2023 Mar;8(1):29Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2023-02-16 / Biochem Biophys Res Commun 2023 Apr;653:106-114Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de